TransThera Sciences (Nanjing) (FRA:J8J) PEG Ratio: N/A (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8J TransThera Sciences (Nanjing) Inc FRA:J8J
20 GF Score
Price €1.05
! 2 Warning Signs
View Full Analysis

What is TransThera Sciences (Nanjing) PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, TransThera Sciences (Nanjing)'s PE Ratio without NRI is 0.00. TransThera Sciences (Nanjing)'s 5-Year EBITDA growth rate is 0.00%. Therefore, TransThera Sciences (Nanjing)'s PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for TransThera Sciences (Nanjing)'s PEG Ratio or its related term are showing as below:



FRA:J8J's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.91
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

TransThera Sciences (Nanjing)  (FRA:J8J) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

TransThera Sciences (Nanjing) PEG Ratio Related Terms

TransThera Sciences (Nanjing) PEG Ratio Historical Data

* Premium members only.

The historical data trend for TransThera Sciences (Nanjing)'s PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransThera Sciences (Nanjing) PEG Ratio Chart

TransThera Sciences (Nanjing) Annual Data
Trend Dec23 Dec24 Dec25
PEG Ratio
0.00 0.00 0.00

TransThera Sciences (Nanjing) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio 0.00 0.00 0.00 0.00 0.00

FRA:J8J vs VRTX, REGN, RVMD: PEG Ratio Comparison

For the Biotechnology subindustry, TransThera Sciences (Nanjing)'s PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransThera Sciences (Nanjing) PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransThera Sciences (Nanjing)'s PEG Ratio distribution charts can be found below:

* The bar in red indicates where TransThera Sciences (Nanjing)'s PEG Ratio falls into.


FRA:J8J
20GF Score
TransThera Sciences (Nanjing) Inc FRA:J8J
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransThera Sciences (Nanjing) PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

TransThera Sciences (Nanjing)'s PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

TransThera Sciences (Nanjing) Business Description

Other Exchanges 02617:Hong Kong
Address Biotech and Pharmaceutical Valley, 3rd floor, Building 9, Accelerator Phase 2, Jiangbei New Area, Jiangsu Province, Nanjing, CHN, 210032
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score

Get the complete analysis for FRA:J8J

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.05
Price